Biomarkers for Presymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients.
Cardiotoxicity of doxorubicin (DOX) remains an important health concern. DOX cardiotoxicity is cumulative-dose-dependent and begins with the first dose of chemotherapy. No biomarker for presymptomatic detection of DOX cardiotoxicity has been validated. Our hypothesis is that peripheral blood cells (...
Main Authors: | Valentina K Todorova, Issam Makhoul, Eric R Siegel, Jeanne Wei, Annjanette Stone, Weleetka Carter, Marjorie L Beggs, Aaron Owen, V Suzanne Klimberg |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4973957?pdf=render |
Similar Items
-
Transcriptome profiling of peripheral blood cells identifies potential biomarkers for doxorubicin cardiotoxicity in a rat model.
by: Valentina K Todorova, et al.
Published: (2012-01-01) -
Correction: Transcriptome Profiling of Peripheral Blood Cells Identifies Potential Biomarkers for Doxorubicin Cardiotoxicity in a Rat Model.
by: Valentina K. Todorova, et al.
Published: (2013-01-01) -
Dantrolene Attenuates Cardiotoxicity of Doxorubicin Without Reducing its Antitumor Efficacy in a Breast Cancer Model
by: Valentina K. Todorova, et al.
Published: (2020-02-01) -
Genome-Wide DNA Methylation Signatures Predict the Early Asymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer
by: Michael A. Bauer, et al.
Published: (2021-12-01) -
Retraction: Biomarkers for Presymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients.
by: PLOS ONE Editors
Published: (2019-01-01)